{"url_path":"/sec/evfm/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1618835/0001493152-26-023928-index.html","accession_number":"0001493152-26-023928","cik":"0001618835","ticker":"EVFM","issuer_name":"Evofem Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1618835/0001493152-26-023928-index.html","primary_entity_key":"0001618835","primary_entity_name":"Evofem Biosciences, Inc."},"word_count":66,"has_tables":true,"body_markdown":"**Item\n5. Other Information**\n\n \n\n \n(a)\nNone.\n\n \n\n \n(b)\nNone.\n\n \n\n \n*(c)*\n*Rule\n10b5-1 Trading Plans*\n\n \n\nDuring\nthe three months ended March 31, 2026, none of our directors or officers entered into, modified, or terminated a “Rule 10b5-1 trading\narrangement” or “non-Rule 10b5-1 trading arrangement,” that were intended to satisfy the affirmative defense conditions\nof Rule 10b5-1, in each case as defined in Item 408 of Regulation S-K.\n\n \n\n52"}